Physician profile
David G Steiner
NPI 1467458661
$55,463.79
in general payments reported to CMS, 2019-2025
71 companies · $4,121 in 2025
The $4,121 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $10K · 2021: $11K · 2022: $8,181 · 2023: $3,682 · 2024: $5,041 · 2025: $4,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,555.23 |
| Education | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23,592.94 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $11,101.72 | 2019 | |
| Harmony Biosciences LLC | $2,113.54 | 2021-2025 | Wakix |
| Abbvie INC. | $1,483.28 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Biogen, INC. | $1,386.00 | 2019-2025 | Vumerity, Leqembi, Plegridy |
| Ani Pharmaceuticals, INC. | $1,199.74 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $1,159.20 | 2019-2025 | |
| Genentech USA, INC. | $947.66 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $926.76 | 2021-2025 | Zeposia |
| Genzyme Corporation | $739.89 | 2019-2023 | |
| Allergan, INC. | $705.27 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $583.63 | 2020-2021 | |
| Lilly USA, LLC | $537.04 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $453.52 | 2020-2025 | Fintepla, Briviact |
| Emd Serono, INC. | $400.95 | 2019-2025 | Mavenclad |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $399.12 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $391.36 | 2021-2025 | Ultomiris, Soliris |
| Pfizer INC. | $371.56 | 2023-2025 | |
| Lundbeck LLC | $357.61 | 2020-2025 | Vyepti |
| Sk Life Science, INC. | $347.67 | 2020-2023 | |
| Tg Therapeutics, INC. | $340.28 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $337.45 | 2020-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $330.30 | 2019-2021 | |
| Eisai INC. | $314.65 | 2020-2025 | |
| Arbor Pharmaceuticals, INC. | $297.12 | 2019-2022 | |
| Livanova USA, INC. | $296.62 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $296.22 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $291.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $268.18 | 2020-2024 | Zeposia |
| Jazz Pharmaceuticals INC. | $264.27 | 2019-2025 | |
| Axsome Therapeutics, INC. | $258.58 | 2025 | Symbravo, Auvelity |
| Supernus Pharmaceuticals, INC. | $210.26 | 2019-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $189.67 | 2021 | |
| Zoll Respicardia, INC. | $167.58 | 2024-2025 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $167.42 | 2024 | Hyqvia |
| Horizon Therapeutics Plc | $167.38 | 2023 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $164.47 | 2019-2025 | Dysport |
| Azurity Pharmaceuticals, INC. | $158.10 | 2023-2025 | Horizant, Horizant |
| Otsuka America Pharmaceutical, INC. | $156.87 | 2023-2024 | Nuedexta, Rexulti |
| Almatica Pharma LLC | $154.73 | 2021-2023 | Gralise |
| Abbott Laboratories | $144.35 | 2020 | |
| Biotronik Nro, INC. | $140.35 | 2025 | Prospera |
| Biohaven Pharmaceutical Holding Company LTD. | $131.47 | 2022 | |
| Avanir Pharmaceuticals, INC. | $91.67 | 2021-2022 | |
| Medtronic, INC. | $87.26 | 2024-2025 | Percept PC Brainsense |
| Scilex Pharmaceuticals INC. | $83.22 | 2024 | |
| Vanda Pharmaceuticals INC. | $82.89 | 2024-2025 | Ponvory |
| Corium, LLC | $80.45 | 2022 | |
| Acorda Therapeutics, INC | $79.22 | 2019-2024 | Ampyra |
| Merz Pharmaceuticals, LLC | $54.71 | 2025 | Inbrija, Xeomin |
| Upsher-Smith Laboratories LLC | $52.05 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $48.29 | 2025 | Crexont |
| Kyowa Kirin, INC. | $41.93 | 2024 | Nourianz |
| Medtronic USA, INC. | $33.96 | 2020 | |
| Ge Healthcare | $32.23 | 2019 | |
| Neurelis, INC. | $30.57 | 2023 | Valtoco |
| International Rehabilitative Sciences, INC | $25.51 | 2025 | Rs-4i Plus With Intersperse |
| Sumitomo Pharma America, INC. | $25.32 | 2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $24.94 | 2025 | |
| Octapharma USA, INC. | $22.18 | 2025 | Panzyga |
| Avadel Cns Pharmaceuticals, LLC | $21.59 | 2024 | Lumryz |
| Impel Pharmaceuticals INC. | $21.43 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.95 | 2023 | |
| Csl Behring | $16.50 | 2023 | Hizentra |
| Banner Life Sciences, LLC | $15.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,119.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.